CHIMERIC THERAPEUTICS LIMITED

0.00%

0.3¢

Market Cap $9.763M

Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company,... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.More

Latest Threads

Tag

Subject

CHM

Ann: Appendix 4E and Annual Report

18:43

3.0K

18:43

Last post dalts66

3.0K

CHM

Ann: Webinar - CHM CDH17 deep dive with Professor Jennifer Eads

01/09/25

5.3K

01/09/25

Last post maxswell

5.3K

CHM

Questions for CHM CDH17 deep dive with Professor Eads

30/08/25

792

30/08/25

Last post KrushingIt

792

CHM

Ann: Corporate Governance Statement and Appendix 4G

29/08/25

173

29/08/25

Last post

ASX News

173

CHM

Ann: Change in substantial holding - PH

25/08/25

16K

25/08/25

Last post dalts66

16K

CHM

CHM related publication

23/08/25

1.1K

23/08/25

Last post KrushingIt

1.1K

CHM

Ann: Change of Director's Interest Notice MP

22/08/25

1.5K

22/08/25

Last post Shellbell

1.5K

CHM

Ann: CHM CDH17 Clinical Trial Update

09/08/25

10K

09/08/25

Last post Aliasdavejay

10K

See All Discussions

Timeline

Corporate Governance Statement and Appendix 4G
29 Aug 16:55	Share

Appendix 4E and Annual Report
29 Aug 16:55	Share

Webinar - CHM CDH17 deep dive with Professor Jennifer Eads
26 Aug 08:27	Share

Change of Director's Interest Notice MP
21 Aug 16:30	Share

Notification regarding unquoted securities - CHM
07 Aug 17:22	Share

Application for quotation of securities - CHM
07 Aug 17:19	Share

CHM CDH17 Clinical Trial Update
04 Aug 08:58	Share

Change in substantial holding - PH
29 Jul 17:05	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Jul 11:34	Share

Proposed issue of securities - CHM
28 Jul 16:56	Share

Notification regarding unquoted securities - CHM
25 Jul 15:27	Share

Application for quotation of securities - CHM
25 Jul 14:47	Share

Notification regarding unquoted securities - CHM
25 Jul 10:24	Share

Application for quotation of securities - CHM
25 Jul 10:10	Share

Update - Proposed issue of securities - CHM
24 Jul 08:39	Share

Proposed issue of securities - CHM
23 Jul 17:03	Share

Prospectus
23 Jul 16:33	Share

Results of Meeting
23 Jul 12:12	Share

Presentation to Extraordinary General Meeting
23 Jul 08:45	Share

Initial Director's Interest Notice
02 Jul 17:07	Share

Change of Director's Interest Notice LR
01 Jul 16:57	Share

Professor Miles Prince appointed as Non-Executive Director
01 Jul 08:35	Share

Notification of cessation of securities - CHM
26 Jun 16:14	Share

Notice of Extraordinary General Meeting/Proxy Form
24 Jun 08:32	Share

Translational data shows persistence of CHM CDH17
17 Jun 08:29	Share

Chimeric receives $2.5 M advance on FY25 R&D tax incentive
10 Jun 12:20	Share

CHM CDH17 receives FDA Fast Track
04 Jun 09:47	Share

Application for quotation of securities - CHM
29 May 16:52	Share

Change in substantial holding - PH
28 May 16:15	Share

Application for quotation of securities - CHM
26 May 15:26	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $9.763M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$8.142K	2.714M

Buyers (Bids)

No.	Vol.	Price($)
54	76345837	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	21817928	8

View Market Depth

No.	Vol.	Price($)
54	76345837	0.002
19	70205047	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	21817928	8
0.004	91701576	55
0.005	39172140	21
0.006	16398222	11
0.007	4279375	5

Last trade - 12.18pm 03/09/2025 (20 minute delay)


Last 0.3¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.3¢	0.3¢	0.3¢	1601592
Last updated 14.11pm 03/09/2025 ?

CHM (ASX) Chart

CHIMERIC THERAPEUTICS LIMITED

Latest Threads

Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion?

Timeline

Featured News

Latest Articles

Chimeric clocks $4.17M R&D tax rebate from Canberra

Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News